Original article
Cromolyn sodium in the management of systemic mastocytosis

https://doi.org/10.1016/0091-6749(90)90067-EGet rights and content

Abstract

A multicenter, double-blind, placebo-controlled trial of the efficacy of oral cromolyn sodium (200 mg orally four times per day) was conducted in 11 patients with systemic mastocytosis who had been maintained with the drug on an individualized compassionate-need basis. Efficacy was measured by physician assessment of overall disease severity based on history and physical examination at specified intervals and by the average daily patient symptom diary scores for each of three mastocytosis-related symptoms that had previously appeared to be alleviated by the use of this drug. Efficacy variables were compared for a 4-week baseline period, during which patients received open-labeled cromolyn sodium, and at 4-week intervals during a 16-week period of random assignment to cromolyn sodium or placebo. Overall disease severity and symptoms recorded in patient diaries were graded on a scale of 0 (absent) to 5 (incapacitating). The average physician assessment of disease severity and symptom scores of the patients in the placebo-treated group increased significantly during the randomization phase relative to patients in the cromolyn sodium-treated group, reflecting an exacerbation of symptoms with drug withdrawal (p < 0.05 and < 0.028, respectively). When the symptom scores were analyzed separately for gastrointestinal manifestations of disease (diarrhea, abdominal pain, nausea, and vomiting), cromolyn sodium treatment was significantly beneficial relative to placebo (p < 0.02), whereas the benefit for nongastrointestinal manifestations did not reach statistical significance.

References (7)

There are more references available in the full text version of this article.

Cited by (152)

  • Treatment of systemic mastocytosis: Novel and emerging therapies

    2021, Annals of Allergy, Asthma and Immunology
    Citation Excerpt :

    For these reasons, treatment with antihistamines is the mainstay of therapy for all forms of mastocytosis. Data to support the use of montelukast12 and oral cromolyn13 are also available. Montelukast is a cysteinyl leukotriene receptor antagonist.

View all citing articles on Scopus

Supported by National Institutes of Health Grants AI-22531, AI-23401, AR-35907, and a grant from the Hyde and Watson Foundation.

View full text